Success Metrics

Clinical Success Rate
96.8%

Based on 30 completed trials

Completion Rate
97%(30/31)
Active Trials
0(0%)
Results Posted
67%(20 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_3
10
29%
Ph not_applicable
3
9%
Ph phase_4
10
29%
Ph phase_2
6
18%
Ph phase_1
4
12%

Phase Distribution

4

Early Stage

6

Mid Stage

20

Late Stage

Phase Distribution33 total trials
Phase 1Safety & dosage
4(12.1%)
Phase 2Efficacy & side effects
6(18.2%)
Phase 3Large-scale testing
10(30.3%)
Phase 4Post-market surveillance
10(30.3%)
N/ANon-phased studies
3(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

30 of 32 finished

Non-Completion Rate

6.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(30)
Terminated(2)
Other(2)

Detailed Status

Completed30
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
96.8%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (12.1%)
Phase 26 (18.2%)
Phase 310 (30.3%)
Phase 410 (30.3%)
N/A3 (9.1%)

Trials by Status

terminated13%
completed3088%
withdrawn13%
unknown26%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT07380178Not Applicable

The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis

Completed
NCT02889809Phase 4

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Completed
NCT05651750Phase 4

Medical vs Surgical Treatment in OSA Among Children

Unknown
NCT05143502Phase 1

Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.

Unknown
NCT03012061Phase 2

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Completed
NCT03898466Phase 4

Effect of Fluticasone Furoate on Methacholine Challenge

Completed
NCT02446418Phase 3

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Completed
NCT03315000Phase 4

Effect of Vilanterol on Methacholine Challenge Results

Completed
NCT03673384Not Applicable

Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

Completed
NCT01313676Phase 3

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Completed
NCT03363191Phase 4

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

Withdrawn
NCT01086384Phase 3

Asthma Exacerbation Study

Completed
NCT02502734Phase 3

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Completed
NCT01159912Phase 3

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Completed
NCT01013701Phase 4

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Terminated
NCT01199757

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Completed
NCT01000597Phase 1

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

Completed
NCT01299558Phase 1

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Completed
NCT01563029Phase 2

A Dose-ranging Study of Fluticasone Furoate (FF)

Completed
NCT02064504Phase 1

Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination

Completed

Drug Details

Intervention Type
OTHER
Total Trials
34